University of Crete (UOC)
Προοπτική μελέτη της δράσης αντινεοπλασματικών φαρμάκων στο Τ-λεμφοκυτταρικό σύστημα
Abstract
dc:descriptionPatients with cancer develop significant deduct of the immune system, which is worsened by the use of antineoplastic agents, since they are active against all regenerated tissues. That often results in severe infections, neutropenic (neutrophils <500/mm³) or non-neutropenic, which can be shared by common microbes or opportunistic infections, usually developed in patients with disorders of cellular immunity. In our study the administration of Docetaxel caused no statistically significant reduction in the absolute number of neutrophils (p=0.065), while the first administration found significant depletion of lymphocytes and CD3+, CD4+, CD8+, CD56+ subpopulations and also, after the second administration, and CD20+. Lymphopenia was partially reversible after discontinuation of the drug (CD3+ and CD4+ returned after 1-3 months, but did not apply the same for CD8+, CD20+, CD56+). There was also increased incidence of non-neutropenic infections in patients who received Docetaxel accompanied by a significant reduction in CD3+, CD4+, CD8+ lymphocytes. In multivariate analysis was established that treatment with Docetaxel represents an independent prognosticative factor of non-neutropenic infections. The mechanism of lymphopenia by Docetaxel is not clarified; however, it seems that has direct effects on lymphocytes (cytotoxicity) at exit from the mitosis, resulting in the increased incidence of non-neutropenic infections. During treatment with Docetaxel, it requires close monitoring of patients for early diagnosis of infections.
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2008
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kotsakis, Athanasios
- Κωτσάκης, Αθανάσιος
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/24976